TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06564038: A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Sponsor: AstraZeneca · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$9,071,370

Rescue Site Savings

+$5,969,040

Unlock Full NCT06564038 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06564038 Rescue Dossier →